Cheryl is an internationally recognized advisor to life sciences companies and some of the industry’s largest investors. She assists clients in developing innovative strategies for domestic and international growth and advises on highly complex transactions around the globe. She represents biotechnology, medical device, and health technology companies at all stages of their development, from inventors and start-ups to major public corporations, as well as venture capitalists, investment banks, and academic medical centers.
By leveraging her deep knowledge of the market and solutions-oriented and practical approach to addressing business issues, Cheryl provides guidance on all aspects of transactions and works with clients to implement optimal corporate and tax structures. She has extensive experience in all aspects of seed, venture, and later-stage financings, IPOs, mergers and acquisitions, licensing transactions, joint ventures, and strategic alliances as well as corporate governance.
Cheryl has worked both in the US and Canada and has deep experience in cross-border issues and planning for US, Canadian, and other foreign clients. Outside of North America, she represents Israeli, European, Australian, Chinese, and Japanese clients.
Cheryl regularly receives recognition and accolades for her work both in the US and Canada. Cheryl was named one of Canada’s Top 100 Most Powerful Women four times by the Women’s Executive Network and inducted into its Hall of Fame. Cheryl has also been repeatedly recognized as the Canadian Finance & Corporate Attorney of the Year by LMG Life Sciences and shortlisted by LMG Life Sciences for US Venture Capital Lawyer of the Year. In addition, she is ranked in Band 1 by Chambers Canada for life sciences corporate/commercial.
Prior to joining Mintz, Cheryl led the Life Sciences Practice of a major Canadian law firm, overseeing a cross-border group of Canadian and US practitioners. Earlier, she directed the 85-attorney life sciences group of a US law firm.
